Executive Director, Global Medical Lead (LC-FAOD, MPS VII and MPS IIIA)

<div class="content-intro"><div><strong>Why Join Us?</strong></div> <div> </div> <div><em>Be a hero for our rare disease patients</em></div> <div><em> </em></div> <div>At Ultragenyx, we fundamentally believe that taking real impactful action to care for the needs of patients and our people is always the right thing to do. To achieve this goal, our vision is to lead the future of rare disease medicine. For us, this means going where other biopharma companies won’t go – challenging the status quo and creating a new model that advances our field so more patients and caregivers can benefit from life-changing treatments. We do this by following the science, applying a novel rapid development approach, making innovative medicines at fair and reasonable prices, and creating a collaborative ecosystem to reach patients in ways that are most meaningful for them. </div> <div> </div> <div>Our commitment and care for patients extends to our people, so culture is an essential cornerstone for Ultragenyx. We remain continuously focused on creating a supportive and inclusive environment of profound learning and growth – so employees can thrive in all areas of their lives, in and outside of work. Ultimately, we want to be an organization where we would be proud for our family, friends and children to work.</div> <div> </div> <div>If you want to have a meaningful impact, do the best work of your career, and grow a lot, both professionally and personally, come join our team<em>. </em></div></div><h3 style="text-align: left;"><strong>Position Summary:</strong></h3> <p>Ultragenyx is seeking an experienced physician leader to serve as Executive Director, Global Medical Affairs Strategy, providing strategic medical leadership across key rare disease programs, including LC‑FAOD, MPS VII, and MPS IIIA.</p> <p>In this role, you will guide global medical strategy for both approved therapies (Dojolvi and Mepsevii) and an investigational AAV gene therapy for MPS IIIA. You will shape and drive integrated evidence generation, scientific communications, external engagement, global launch preparation, and lifecycle strategy across a diverse and evolving portfolio.</p> <p>Reporting to the VP, Global US Medical Affairs and Strategy, the Executive Director will operate as a trusted scientific and strategic leader—collaborating cross‑functionally, influencing decisively, and navigating the complexities of metabolic and neurodegenerative genetic diseases. This is a high‑impact, career‑defining opportunity for a medical affairs leader passionate about advancing the future of rare disease medicine.</p> <p style="text-align: left;"><em><strong>ultra</strong>innovative – Tackle rare and dynamic challenges<br></em></p> <h3 style="text-align: left;"><strong>Work Model: </strong></h3> <p style="text-align: left;">Remote: Officially documented as working full-time from home, with travel to Ultragenyx's offices or other locations on occasion as needed.</p> <h3 style="text-align: left;"><strong>Responsibilities:</strong></h3> <ul> <li>Serve as Global Medical Lead for LC-FAOD (Dojolvi) and the MPS programs, including MPS VII (Mepsevii) and MPS IIIA (UX111)</li> <li>Lead the Global Medical Sub Teams (GMSTs), setting the strategy for the programs, ensuring cross regional alignment, and driving timely execution of annual medical plan</li> <li>Guide and oversee prelaunch planning, launch execution, and postlaunch optimization across the globe</li> <li>Serve as the strategic medical leader on the Program Core Team and related sub-teams, shaping development, commercialization, and lifecycle strategies. Work decisively to overcome challenges and drive program priorities forward</li> <li>Own, develop, and update the Integrated Evidence Generation Plans (IEPs) for all assigned programs ensuring cross functional alignment to address global/regional evidence gaps </li> <li>Oversee global Real World Evidence initiatives, including ISTs and collaborative research that inform clinical deci ... (truncated, view full listing at source)